Promimic AB (publ) (PRO.ST)
SEK 26.1
(-8.74%)
SEK 26.1
(-8.74%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 330 Thousand SEK | 80.33% |
| 2022 | 183 Thousand SEK | 30.71% |
| 2021 | 140 Thousand SEK | 250.0% |
| 2020 | 40 Thousand SEK | 0.0% |
| 2019 | 40 Thousand SEK | 109.84% |
| 2018 | 19.06 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 627 Thousand SEK | 26.41% |
| 2024 Q1 | 496 Thousand SEK | 50.3% |
| 2023 Q2 | 342 Thousand SEK | 47.41% |
| 2023 FY | 330 Thousand SEK | 80.33% |
| 2023 Q4 | 330 Thousand SEK | -32.93% |
| 2023 Q3 | 492 Thousand SEK | 43.86% |
| 2023 Q1 | 232 Thousand SEK | 26.78% |
| 2022 Q2 | 85 Thousand SEK | -20.56% |
| 2022 Q4 | 183 Thousand SEK | 19.61% |
| 2022 Q3 | 153 Thousand SEK | 80.0% |
| 2022 FY | 183 Thousand SEK | 30.71% |
| 2022 Q1 | 107 Thousand SEK | -23.57% |
| 2021 Q4 | 140 Thousand SEK | 204.35% |
| 2021 Q3 | 46 Thousand SEK | 142.11% |
| 2021 FY | 140 Thousand SEK | 250.0% |
| 2021 Q2 | 19 Thousand SEK | -70.31% |
| 2021 Q1 | 64 Thousand SEK | 0.0% |
| 2020 FY | 40 Thousand SEK | 0.0% |
| 2019 FY | 40 Thousand SEK | 109.84% |
| 2018 FY | 19.06 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | 95.175% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 99.728% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 99.728% |
| Arcoma AB | 28.02 Million SEK | 98.823% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | 98.887% |
| BICO Group AB (publ) | 493.1 Million SEK | 99.933% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 99.471% |
| CellaVision AB (publ) | 126.03 Million SEK | 99.738% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | 94.603% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | 81.366% |
| C-Rad AB (publ) | 64.09 Million SEK | 99.485% |
| Duearity AB (publ) | 4.15 Million SEK | 92.065% |
| Dignitana AB (publ) | 7.41 Million SEK | 95.548% |
| Episurf Medical AB (publ) | 3.7 Million SEK | 91.081% |
| Getinge AB (publ) | 6.41 Billion SEK | 99.995% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 119.604% |
| Iconovo AB (publ) | -4.86 Million SEK | 106.787% |
| Integrum AB (publ) | 22.36 Million SEK | 98.524% |
| Luxbright AB (publ) | 8000.00 SEK | -4025.0% |
| Mentice AB (publ) | 14.1 Million SEK | 97.66% |
| OssDsign AB (publ) | 4.3 Million SEK | 92.333% |
| Paxman AB (publ) | 19.99 Million SEK | 98.35% |
| Qlife Holding AB (publ) | 7.29 Million SEK | 95.474% |
| SciBase Holding AB (publ) | 11.91 Million SEK | 97.231% |
| ScandiDos AB (publ) | 22.69 Million SEK | 98.546% |
| Sectra AB (publ) | 36.59 Million SEK | 99.098% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 99.232% |
| Senzime AB (publ) | 20.34 Million SEK | 98.378% |
| SpectraCure AB (publ) | 1.00 SEK | -32999900.0% |
| Stille AB | 66.55 Million SEK | 99.504% |
| Vitrolife AB (publ) | 413 Million SEK | 99.92% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 99.767% |